Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Q&A: Martin Kramer, Managing Partner, Ceptar Consulting

    Secondary Life Markets April 10, 2025By Greg Winterton
    Share
    Twitter LinkedIn Email

    The life settlement industry’s tertiary market is an opaque one, with many of the transactions being conducted on an over-the-counter, bilateral basis. Greg Winterton caught up with Martin Kramer, Managing Partner at Ceptar Consulting, to find out what’s been happing in this part of the life settlement world. 

    GW: Martin – let’s begin with a look back on the start of this year. Has the first quarter of 2025 delivered more activity in terms of deal flow in the tertiary market, or less, and why? 

    MK: Greg – thanks so much for having me. In terms of market activity, I have seen more transactions so far in 2025 compared to the first quarter of last year, with a few large capital sources that are deploying money into the space. But I would also say that since it is still early in the year, we don’t know for certain if some or all of the portfolios that are being shopped at the moment will transact. Last year (2024) saw at one notably large portfolio transacting, which is something that, in terms of size, we haven’t seen this year yet, but there is, of course, plenty of time left and we’ll know more as the year progresses. But the tertiary market is definitely off to a busier start than it was in Q1 2024. 

    GW: What’s your view on the ‘health’ – pardon the pun – of life settlement portfolios in the tertiary market when it comes to up-to-date LE’s? Are sellers bringing blocks of business that have better information for the buyer(s)? 

    MK: I don’t really see life settlement portfolios with really stale LEs anymore. The market has gotten much better in that regard. Most portfolios in the tertiary market now have at least one LE that is only a few years old – years ago, it was easier for sellers to sell-on really old LEs and still achieve competitive IRRs but not anymore. In terms of origination quality, there is still a considerable number of cases with origination risk floating around in the market, and market participants need to form their own view on whether to accept this risk in exchange for a more aggressive discount rate or not. 

    GW: ELSA has developed its Master Agreement for Tertiary Transactions (MATT) but aside from that there is a lack of standardisation in terms of policy documentation – and valuation methodology – in the tertiary space. How much of a roadblock is this to getting more deals done here? 

    MK: First of all, I would like to commend ELSA on creating the MATT and making it available to all its members – ELSA is the only organization that has managed to produce a standard document for parties to transact on and that should be applauded. As for whether more standardization is a good thing, I would like to play the devil’s advocate here, and argue that standardization, in general, would pose more risks than benefits to our industry because the difference in valuation methodologies between asset managers/policy buyers, and market participants taking different views on origination risk, LE underwriting etc., is what the tertiary market thrives on. With more standardization – such as in policy valuation, for example – there would likely be a much lower level of activity as fewer firms would be able to differentiate their offering and create some kind of edge. 

    GW: What is the ratio of ‘distressed’ portfolios – where the seller needs to sell – to non-distressed (where the seller is just shopping around) in the tertiary market? I assume distressed blocks see opportunistic bidders looking for a bargain. 

    MK: This year (2025) is only a few months old and it might be a little too early to tell what the exact ratio is. However, I am fairly certain that the number of distressed sellers will increase this year compared to 2024. Interest rates in the US haven’t come down yet this year, which means that the cost of capital (and with it, the borrowing cost) remains relatively high. If interest rates were only temporarily high, some investors might try to ride it out by restructuring debt or raising capital. However, if rates stay at or around their current levels for an extended period, the financial strain accumulates, making distress more likely, forcing more sales into the tertiary market. Add to that those that have suffered from subpar mortality performance, or capital redemptions, and you might see some managers finding that there is an increasing gap between their bookmarks, and where the market is currently trading at. 

    GW: Lastly, Martin, what’s the outlook for the rest of the year? What are the chances that deal activity increases or decreases, and why? 

    MK: I am fairly certain that transaction volume in the tertiary market will go up in 2025, in part due to what I said about the likelihood of more distressed portfolios. There is sufficient capital in the market looking for a chance to deploy so there is no demand issue, it’s a supply one. The challenge will be whether the seller’s expectations in terms of price align with where the market is actually trading in 2025. 

    Martin Kramer is Managing Partner at Ceptar Consulting 

    2025 - March Life Settlements Longevity Risk Q&A Volume 4 Issue 3 - March 2025
    Share. Twitter LinkedIn Email

    Related Posts

    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026By Greg Winterton

    Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

    November 11, 2026By LMI Newsdesk

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026By Greg Winterton

    Q&A: Alexandr Dudarev, CEO, Inshurik

    October 28, 2026By Greg Winterton
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.